ELLORARXINE
Live / Registered — Registered (as of 23 Jul 2024)
What this means for you
Registered since 23 Jul 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98055920
- Registration number
- 7454536
- Mark type
- Stylized text
- Filed
- 23 Jun 2023
- Published for opposition
- 07 May 2024
- Registered
- 23 Jul 2024
- Attorney of record
- Ira E. Silfin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical compositions and preparations for the treatment of neuropathic pain, neurodegenerative diseases, neurological conditions, and degenerative brain diseases; pharmaceutical compositions and preparations for the treatment of schizophrenia, Amyotrophic lateral 15 sclerosis (ALS), Parkinson's disease, multiple sclerosis (MS), Alzheimer's disease, motor neurone disease, cognitive disorders, memory impairment, memory deficit, senile dementia, cognitive impairment, stroke, traumatic brain injury, epilepsy, and spinal cord injury; pharmaceutical compositions and preparations for the treatment of retinoic acid receptor mediated diseases; anti-inflammatory pharmaceuticals
Owner
- Nevrargenics Limited, Durham, GB
- Nevrargenics Limited, Durham, GB
- Nevrargenics Limited, Durham, GB
Prosecution history
- 23 Jul 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 23 Jul 2024 — REGISTERED-PRINCIPAL REGISTER
- 07 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 May 2024 — PUBLISHED FOR OPPOSITION
- 17 Apr 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Apr 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Mar 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Mar 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Mar 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 15 Mar 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 15 Mar 2024 — NON-FINAL ACTION E-MAILED
- 15 Mar 2024 — NON-FINAL ACTION WRITTEN
- 11 Mar 2024 — ASSIGNED TO EXAMINER
- 25 Jul 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Jun 2023 — NEW APPLICATION ENTERED